Related by context. All words. (Click for frequent words.) 78 pharmacokinetic PK 77 pharmacokinetics PK 74 pharmacodynamic 73 pharmacodynamic effects 73 viral kinetics 73 pharmacodynamics PD 72 vidofludimus 72 fosbretabulin 72 pharmacokinetic parameters 72 safety tolerability pharmacokinetic 72 favorable pharmacokinetic profile 71 preclinical efficacy 71 plasma pharmacokinetics 71 pharmacodynamic markers 71 analgesic efficacy 70 pharmacodynamic endpoints 70 pharmacodynamic parameters 70 favorable pharmacokinetic 70 GMX# 70 GAMMAGARD 70 pharmacokinetic PK profile 70 Pharmacokinetics PK 70 Pharmacodynamic 70 ENMD # 70 Pharmacokinetic 70 MGd 70 CLORETAZINE TM VNP#M 70 biodistribution 69 tumorigenicity 69 tolerability pharmacokinetics 69 pharmacokinetic 69 anti leukemic 69 antiviral efficacy 69 alvespimycin 69 non nucleoside 69 Phase Ib clinical 69 phase Ib 69 pharmacodynamic properties 69 INCB# [001] 69 immune modulating 69 Phase Ib study 69 PSMA ADC 69 intravesical 69 Xanafide 69 pharmacodynamic profile 69 AST ALT 69 velafermin 69 erythropoietic 69 selective modulator 69 PKC# 69 gemcitabine Gemzar ® 69 pharmacodynamics 68 Phase 1a clinical 68 riociguat 68 pharmacokinetics pharmacodynamics 68 MAGE A3 ASCI 68 cannabinor 68 Apoptone 68 oral prodrug 68 receptor inhibitor 68 neratinib 68 pharmacokinetic PK study 68 tolerability profiles 68 BrachySil TM 68 HER2 expression 68 effector function 68 preclinically 68 demonstrated antitumor activity 68 Pharmacokinetic studies 68 Primary endpoints 68 HGS ETR2 68 pharmacokinetic pharmacodynamic 68 nucleotide analog 68 HuMax EGFr 68 antiangiogenic agents 68 imetelstat 68 immunomodulation 68 huN# DM1 67 LB# [003] 67 maximally tolerated dose 67 antiangiogenic therapy 67 murine model 67 crizotinib PF # 67 Pharmacokinetic PK 67 intracoronary 67 ALB # 67 murine models 67 PXD# 67 TPI ASM8 67 CDK inhibitor 67 Cloretazine 67 varespladib 67 relapsed MM 67 Azedra 67 busulfan 67 AT1R 67 Phase 1b 67 serum cortisol 67 pain palliation 67 cardiac repolarization 67 ascending dose 67 pharmacokinetic profile 67 systemically administered 67 pharmacokinetic profiles 67 prospectively defined 67 MVA MUC1 IL2 67 ara C 67 novel VDA molecule 67 galiximab 67 rHuPH# 67 bortezomib Velcade 67 ELACYT 67 interleukin IL -# 67 pharmacodynamic profiles 67 bronchodilatory 67 rhITF 67 inhaled iloprost 67 Phase Ib II 67 vivo potency 67 Phase 2a trial 67 Phase 1a 67 LAB CGRP 67 lenalidomide dexamethasone 67 xenograft models 67 antitumor activity 66 clinicopathological features 66 EDEMA3 trial 66 XmAb# 66 pharmacokinetic studies 66 urocortin 2 66 immunological responses 66 EGFR HER2 66 trodusquemine 66 pharmacokinetics 66 Trofex 66 thorough QT 66 chemosensitivity 66 Kinoid 66 BAL# [002] 66 interferon γ 66 refractory prostate cancer 66 p# inhibitor 66 Panzem R NCD 66 XL# inhibits 66 CCX# 66 liposomal formulation 66 pharmacokinetic equivalence 66 Enzastaurin 66 Valortim ® 66 epoetin alpha 66 ganetespib 66 selective agonist 66 Capesaris 66 urate lowering 66 dose cohort 66 enzastaurin 66 haematologic 66 DLTs 66 CTAP# Capsules 66 demonstrated clinically meaningful 66 forodesine 66 cobiprostone 66 mecamylamine 66 Secondary endpoints include 66 p# biomarker 66 Valortim R 66 Posiphen 66 lactate dehydrogenase LDH 66 mTOR inhibition 66 antitumor efficacy 66 orally bioavailable 66 MetMAb 66 Forodesine HCl 66 vitro experiments 66 Symadex 66 ruxolitinib 66 phase IIa clinical 66 EGFR TKIs 66 NOD SCID mice 66 vWF 66 MEND CABG II 66 NP2 Enkephalin 66 hematological parameters 66 Phase #b/#a 66 recurrent glioblastoma multiforme 66 antitumor effect 66 immune modulatory 66 solithromycin 66 PRTX 66 lymphoid malignancies 66 tanespimycin 66 dosing cohort 66 antiapoptotic 66 null responder 66 R baclofen 66 farletuzumab 65 myeloproliferative diseases 65 GRNCM1 65 TOLAMBA 65 dosage regimens 65 antiangiogenic agent 65 desvenlafaxine succinate 65 orally dosed 65 Archexin 65 clevidipine 65 L PPDS 65 Phase IIB 65 dose proportionality 65 tissue oxygenation 65 CR# vcMMAE 65 liposomal amphotericin B 65 intravenous dosing 65 NOX E# 65 CYT# potent vascular disrupting 65 CIMZIA ™ 65 acadesine 65 radiolabeled 65 Phase Ib 65 receptor antagonism 65 neurologic progression 65 STRIDE PD 65 ritonavir boosted 65 serum PTH 65 prucalopride 65 uricase 65 histone deacetylase inhibitor 65 nab paclitaxel 65 GHRH 65 etiologic 65 Multimeric 65 Omacetaxine mepesuccinate 65 topoisomerase II inhibitor 65 HIF PH inhibitors 65 eniluracil 65 mertansine 65 depsipeptide 65 selectively inhibited 65 HepG2 cells 65 Traficet EN 65 pharmacokinetic characteristics 65 melphalan prednisone 65 SSc 65 CG# [003] 65 eTag assays 65 fibrotic disease 65 VP# [004] 65 immunotoxicity 65 cilengitide 65 triphendiol 65 teriflunomide 65 ON #.Na 65 humoral responses 65 Tarceva TM 65 HGS ETR1 65 transgene expression 65 erlotinib Tarceva ® 65 APTIVUS 65 clinically meaningful improvement 65 phase 2a 65 rBChE 65 DermaVir Patch 65 treatment naive genotype 65 Phase #b/#a trial 65 Triapine R 65 Onconase 65 antiproliferative 65 hyperoxaluria 65 alagebrium 65 bronchial hyperresponsiveness 65 JVRS 65 kinase inhibition 65 LPS induced 65 AKT inhibitor 65 PEGPH# 65 mg kg BID 65 JAK2 inhibitor 65 #ME# 65 hyaluronidase enzyme 65 sitaxsentan 65 airway hyperresponsiveness 65 KRAS status 65 JAK inhibitor 65 reactogenicity 65 Lp PLA 2 65 ATL# [001] 65 cytoprotective 65 estramustine 65 CIMZIA R 65 prognostic significance 65 liver histology 65 subcutaneous SC 65 PI3K/mTOR 65 LEP ETU 65 tipranavir r 65 multicenter Phase II 65 receptor tyrosine kinase inhibitor 65 radiation dosimetry 65 evaluating tivozanib 65 hENT1 65 neuroregenerative 65 enzyme inhibition 65 Ophena TM 65 OMP #M# 65 serum concentrations 65 ERK signaling 65 5 HT2A 65 viral kinetic 65 tryptase 65 blinded randomized placebo controlled 65 preclinical pharmacokinetic 65 limiting toxicity DLT 65 Kahalalide F 65 GLP toxicology studies 65 pomalidomide 65 Virulizin ® 65 CardioPET 65 antitumour activity 65 fluticasone furoate 65 inhibitor RG# 65 CANCIDAS 65 huC# DM4 65 potent antiproliferative 64 ascending doses 64 mGluR5 NAM 64 IL 1ß 64 certolizumab 64 ISTODAX 64 antibody MAb 64 favorable tolerability 64 Zemplar Capsules 64 tipifarnib 64 CIMZIA TM 64 lintuzumab 64 genotypic resistance 64 mouse xenograft models 64 Hsp# Inhibitor 64 tolerated dose MTD 64 subcutaneously administered 64 randomized Phase 2b 64 pretransplant 64 novel histone deacetylase 64 imatinib therapy 64 MEND CABG 64 Aplidin 64 mRNA expression 64 cMET 64 selective inhibition 64 nonrandomized 64 phase IIb trial 64 serum phosphorous 64 CBLC# 64 pharmacokinetic properties 64 GRN#L 64 PDE4 inhibitor 64 OXi# 64 alemtuzumab MS 64 PRT# 64 monoclonal anti 64 optimal dosing regimens 64 phase IIb study 64 papillary renal cell carcinoma 64 HIV coinfected 64 Bezielle 64 undetectable HBV DNA 64 Pharmacokinetic parameters 64 dose limiting toxicities 64 Alkaline Phosphatase 64 Phase Ia 64 efficacy tolerability 64 Gleevec resistant 64 Androxal TM 64 prostanoid 64 humanized monoclonal 64 Ceplene/IL-2 64 potently inhibited 64 posaconazole 64 KRAS mutation status 64 pertussis toxin 64 MP4OX 64 Panzem R 64 Squalamine 64 heavily pretreated 64 hyperphenylalaninemia HPA due 64 Phase IIb III 64 intracellular uptake 64 plasma lipid 64 placebo controlled clinical 64 receptor subtypes 64 Blinatumomab 64 PEG IFN 64 PEGylated interferon 64 tubulin inhibitor 64 IIa trial 64 APTIVUS r 64 pertuzumab 64 Chemophase 64 cTnI 64 p# activation 64 surrogate endpoint 64 Secondary endpoints 64 Thiovir 64 liposomal doxorubicin 64 5alpha reductase 64 isoform selective 64 GLYX 64 anticancer activity 64 C1 INH 64 prognostic biomarker 64 mTOR inhibitors 64 trastuzumab Herceptin ® 64 azacytidine 64 phase IIa 64 CTA# 64 ARIKACE ™ 64 tolerability 64 optimal dosing 64 coadministration 64 cariprazine 64 EOquin TM 64 somatostatin analog 64 Preclinical studies suggest 64 Secondary endpoints included 64 serum lipid 64 MDS AML 64 polycythemia vera PV 64 pharmacokinetic interactions 64 ritonavir boosting 64 Phase IIIb clinical 64 gemcitabine carboplatin 64 sargramostim 64 intradermal injection 64 QT QTc 64 serum antibody 64 peptide conjugated 64 Akt activation 64 indibulin 64 safety tolerability pharmacokinetics 64 ATL/TV# 64 Anticalins ® 64 PENNVAX B 64 Phase 1b trial 64 trastuzumab emtansine T DM1 64 tezampanel NGX# 64 Antiviral Activity 64 intranasal delivery 64 Platinol ® cisplatin 64 vascular disrupting agents 64 AEGR 64 S/GSK# 64 growth hormone secretion 64 epigenetic therapies 64 endothelial activation 64 immunoreactivity 64 immunofluorescence staining 64 tumor lysis syndrome 64 NGX# 64 QTc prolongation 64 CIMZIA TM certolizumab pegol 64 CA4P 64 syngeneic 64 nonclinical studies 64 Natalizumab 64 CINQUIL 64 mGluR2 NAM 64 alicaforsen enema 64 hA# 64 neuroprotective properties 64 F FDG PET 64 aplindore 64 liposome formulation 64 EOquin 64 hemodynamic variables 64 Tyrosine Kinase Inhibitor 64 safety tolerability 64 urinary N telopeptide 64 Imprime PGG 64 clinicopathological 63 taxane resistant 63 TIMP 1 63 pharmacodynamic biomarkers 63 IFN α 63 intestinal permeability 63 AAG geldanamycin analog 63 K ras mutations 63 highly immunogenic 63 inecalcitol 63 limiting toxicity 63 glycosylated hemoglobin HbA1c 63 lomitapide 63 administered subcutaneously 63 immunomodulatory effects 63 metaglidasen 63 confirmatory clinical 63 TRV# [001] 63 Altastaph 63 REMINYL ® 63 dose escalation phase 63 SERCA2a 63 catheter occlusion 63 ChronVac C R 63 potency selectivity 63 glycosylated hemoglobin levels 63 HDL Selective Delipidation 63 plasma renin activity 63 HCD# [002] 63 pramlintide metreleptin combination 63 mg/m2 cohort 63 antibody titer 63 GOUT 63 hepatic fibrosis 63 prognostic indicators 63 immunogenicity 63 bendamustine 63 radiotherapy RT 63 Lenalidomide 63 Vascugel ® 63 TransVax ™ 63 Multiple Ascending Dose 63 ispinesib administered 63 molecular biomarkers 63 RLY# 63 JAK inhibitors 63 Estrogen Receptor 63 serologic 63 milatuzumab 63 randomized multicenter trial 63 Immunohistochemical analysis 63 IGF 1R inhibitor 63 HIF 1a 63 #ß 63 TNFalpha 63 TG# [001] 63 tumor histology 63 CCR5 mAb 63 IAP inhibitor 63 inhibitory effects 63 lorvotuzumab mertansine 63 immunostimulatory 63 airway responsiveness 63 Secondary efficacy endpoints 63 inotropic 63 tumor hypoxia 63 Pralatrexate 63 metastatic neuroendocrine tumors 63 experimentally induced 63 beta 1a 63 antiangiogenic 63 antidepressant efficacy 63 TMC# [002] 63 virological response 63 radiolabeled TM# 63 heparanase 63 low dose cytarabine 63 PhG alpha 1 63 CRLX# 63 demyelinating 63 mediated inhibition 63 potent inhibition 63 MAXY G# 63 selective adenosine 63 kallikrein 63 PK PD 63 aminotransferase 63 YONDELIS 63 JAK2 V#F 63 Exherin TM 63 Tyrima 63 noninferiority 63 p# mitogen activated 63 antitumoral 63 Liposomal 63 intradermal injections 63 HER2 positive metastatic breast 63 selective antagonist 63 immunomodulatory therapy 63 Cloretazine R VNP#M 63 Phase Ib clinical trials 63 VAPRISOL 63 investigational humanized monoclonal antibody 63 Seliciclib 63 R# #mg BID 63 pharmacologic 63 PI3K/Akt pathway inhibitor 63 gefitinib Iressa 63 AQ4N 63 CCR9 63 genomic biomarker 63 LHRH antagonists 63 cystinosis patients 63 IMC A# 63 caspofungin 63 plasma leptin 63 BNC# 63 phase IIb clinical 63 RezularTM 63 EGS# 63 scintigraphic 63 Degarelix 63 orally administered inhibitor 63 replicon 63 microsomal 63 salmeterol fluticasone 63 Interferon beta 1a 63 Aplidin R 63 genotypic 63 intratumoral 63 vivo preclinical 63 P#Y# [002] 63 adipogenic 63 ADAGIO study 63 cynomolgus monkeys 63 Omacetaxine 63 elotuzumab 63 hMG 63 HuLuc# 63 Tolerability 63 neurotrophic 63 UPLYSO 63 glucose homeostasis 63 microvessel density 63 weekly subcutaneous injections 63 ORMD 63 Tasimelteon 63 hemagglutination inhibition 63 Genz # 63 Denufosol 63 MYLOTARG 63 celgosivir 63 genotoxicity 63 potent cytotoxic 63 DAVANAT 63 davunetide intranasal AL 63 generation purine nucleoside 63 R#/MEM # 63 endothelin antagonists 63 multiple ascending dose 63 ABSSSI 63 eculizumab therapy 63 metastatic malignant 63 ataluren 63 prospective multicentre 63 Corgentin 63 GAP #B# 63 locoregional disease 63 BRIM2 63 masitinib 63 im peramivir 63 Telintra 63 sorafenib Nexavar 63 colorectal adenoma 63 neutralizing antibody 63 PI3K inhibitor 63 neutropaenia 63 sipuleucel T 63 gemtuzumab ozogamicin 63 relapsing multiple sclerosis 63 neovascular 63 osteogenic 63 elacytarabine 63 Vacc 4x 63 serum aminotransferase levels 63 PIK3CA 63 #F FDG PET 63 corticosteroid dose 63 NeuroSTAT ® 63 Triolex 63 mg kg dose 63 secondary efficacy endpoints 63 inhaled AAT 63 generation antisense inhibitor 63 Acute Ischemic Stroke 63 echocardiographic parameters 63 isotype 63 IntroductionThe 63 haematopoietic 63 RAV# 63 sorafenib Nexavar ® 63 carcinoembryonic antigen 63 immunohistochemical 63 bronchoalveolar lavage 63 DepoVax 63 DCCR 63 Tumor Response 63 muscarinic 63 antiproliferative activity 63 vasoactive 63 topically administered 63 Darinaparsin 63 HGS# 63 avosentan 63 lesional 63 Lenocta 63 TransVax tm 63 Phase 1b clinical 63 BrachySil ™ 63 pulmonary exacerbations 63 Phase #/#a 63 nicardipine 63 potent neuroprotective 63 antiproliferative effects 63 hematologic parameters 63 Phase 2a clinical 63 NEUMUNE 63 PC# cells 63 CYT# 63 Teriflunomide 63 CEACAM1 63 prospectively stratified 63 immunologic 63 Xelox 63 tumor necrosis 63 Transported Prodrug 63 potently inhibits 63 vorinostat 63 GSK# [001] 63 alkylating agent 63 MGN# 62 pathophysiological effects 62 biomarker assay 62 gemcitabine cisplatin 62 hypoxia activated prodrug 62 apolipoprotein B 62 Angiotensin converting enzyme 62 ZACTIMA 62 β blockers 62 Curaxin CBLC# 62 VELCADE melphalan 62 dasatinib Sprycel 62 imatinib resistant 62 dose escalation 62 cytotoxicity 62 alkaline phosphatase ALP 62 omega interferon 62 thetreatment 62 MAP# 62 panobinostat 62 histone acetyltransferase 62 PET tracer 62 CoFactor 62 targeted antifolate 62 GRASPA ® 62 FDG PET imaging 62 Cimzia TM 62 VNP#M 62 IFN beta 62 GSTP1 62 peptide antigens 62 neoadjuvant chemotherapy 62 BRAF V#E mutation 62 serum phosphate 62 activating mutation 62 oral rivaroxaban 62 serum leptin 62 ganaxolone 62 OHR/AVR# 62 Vitaxin 62 canakinumab 62 Platinol ® 62 PRIMO CABG2 62 pDCs 62 selective agonists 62 efficacy endpoint 62 Antiangiogenic 62 Anticalins R 62 SPRYCEL ® 62 NSABP B 62 5 HT2C receptor 62 multicenter randomized placebo controlled 62 DDP# 62 SNT MC# 62 refractory CLL 62 interferon IFN 62 anti amnesic 62 physiologically relevant 62 INT# [002] 62 bleomycin 62 Spiegelmer ® 62 Tasigna prolongs 62 GH deficiency 62 paraprotein 62 zonisamide SR 62 oblimersen 62 relapsed ALL 62 IMGN# 62 plasma kallikrein inhibitor 62 EGFR mutation status 62 paricalcitol 62 paclitaxel poliglumex 62 Panzem ® 62 OvaRex R 62 ^ Tc 62 ultrastructural 62 radiosensitivity 62 AeroLEF TM 62 immunostimulatory effects 62 urothelial 62 CGRP 62 independent prognostic marker 62 Factor VIIa 62 oxidative stress markers 62 Protein Kinase C 62 SCH # 62 liver transaminases 62 fluoropyrimidine 62 NATRECOR ® 62 orally inhaled 62 INVEGA ® 62 potent antitumor 62 prostate cancer PCa 62 Zybrestat 62 p# biomarkers 62 INCB# [003] 62 Vidaza azacitidine 62 abacavir Ziagen 62 achieved statistical significance 62 humanised monoclonal antibody 62 microtubule inhibitor 62 cinacalcet 62 HCV protease inhibitors 62 IIa trials 62 molecular remissions 62 electrophysiologic 62 intestinal mucosal 62 axitinib 62 PPAR gamma agonist 62 progression TTP 62 PEG SN# 62 antioxidant supplementation 62 florbetaben 62 Inhaled AAT 62 Th2 cytokines 62 O PPDS 62 Poly ICLC 62 TO AVOID PREGNANCY WHILE 62 prostate cancer CaP 62 pretreatment serum 62 elastase 62 prostate carcinoma 62 TLK# 62 cytotoxic effects 62 subcutaneous PRO 62 OMNARIS HFA 62 Amphinex ® 62 predictive biomarker 62 Vaxfectin TM 62 trastuzumab DM1 T DM1 62 VKORC1 62 RSD# oral 62 taxane therapy 62 CD# upregulation 62 LSI #P 62 CA9 SCAN 62 Aclidinium 62 antithrombotic 62 intravascular hemolysis 62 Inosine 62 decitabine 62 Temsirolimus 62 GPx 62 mg/m2 dose 62 CCyR 62 Prodarsan ® 62 #beta estradiol 62 denileukin diftitox 62 interferon gamma 1b 62 Solid Tumors criteria 62 FOLFOX6 chemotherapy regimen 62 histologically confirmed 62 TAKSTA 62 adenoviral 62 plasma kallikrein 62 alpha#beta# integrin 62 Immunomodulatory 62 novel emulsion formulation 62 5 fluorouracil leucovorin 62 intact parathyroid hormone 62 sUA 62 maturation inhibitor 62 Aurora Kinase 62 cardioprotective effects 62 intratumoral injection 62 Phase IIa clinical 62 BIM #A# 62 azilsartan medoxomil 62 BEXXAR Therapeutic Regimen 62 tasimelteon 62 colorectal liver metastases 62 Pharmacodynamics 62 CINTREDEKIN BESUDOTOX 62 LHRH receptor 62 histological subtype 62 antitumor 62 IgG antibody 62 uric acid lowering 62 cardiac contractility 62 cytostatic 62 peripheral blood mononuclear 62 potent anti angiogenic 62 TRAIL induced apoptosis 62 R#/MEM 62 aerosolized KL4 surfactant 62 Phase #b/#a clinical 62 ERK1 2 62 sulodexide 62 HCV replicon 62 vinca alkaloid 62 thrombin receptor 62 natriuretic peptide 62 promoter methylation 62 Phase 2b study 62 oral FTY# 62 neoadjuvant 62 DAS# CRP 62 inflammatory biomarkers 62 Pivotal Phase III 62 TRO# 62 bronchodilation 62 QLT# 62 Phase IIa trials 62 clinically relevant 62 HQK 62 Bendavia 62 PBMCs 62 serum albumin 62 inverse agonist 62 AEG# 62 immunohistochemical analysis 62 Bioavailability 62 inducible nitric oxide synthase 62 Catena ® 62 DermaVir 62 oral picoplatin 62 aMCI precursor 62 statistically significant efficacy 62 Hepatotoxicity 62 antiarrhythmic 62 confirmatory Phase III 62 retaspimycin 62 anti CD3 62 RECIST Response Evaluation Criteria 62 CanAg 62 anti HBs 62 synthetic retinoid 62 nicotinic acetylcholine receptor 62 lactate dehydrogenase 62 APPRAISE 62 HSP# inhibitor 62 dose cohorts 62 dose escalation study 62 peptide receptor 62 bevacizumab Avastin ® 62 micafungin 62 PD LID 62 Elevated serum 62 Aptivus ® 62 vitro cytotoxicity 62 TAXUS VI 62 tyrosine phosphorylation 62 potent antitumor activity 62 menadione 62 REVIVE Diabetes 62 hemodynamic measurements 62 thyroid carcinoma 62 thalidomide Thalomid 62 CEQ# 62 cytotoxicity assays 62 Novolimus 62 IFN γ 62 histopathological 62 Octreolin 62 RG# [001] 62 synthetic siRNA 62 metabolic parameters 62 basal bolus regimen 62 Safinamide 62 PDGF receptor 62 Kamada AAT 62 xenograft model 62 r hGH 62 HMG CoA reductase inhibitors 62 intranasal formulation 62 systemic hypotension 62 galectin 62 tumor subtypes 62 assessing T DM1 62 dose dependently 62 myopathy rhabdomyolysis 62 Solorel TM 62 Phase IIb clinical trials 62 Universal Flu Vaccine 62 striatal dopamine 62 RRM1 62 metabolite concentrations 62 mitogenic 62 dose escalation Phase 62 pro angiogenic 62 CD# expression [002] 62 oral methylnaltrexone 62 Hsp# inhibition